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Background. Liver resection in metastatic colorectal cancer is proved to result in ﬁve-year survival of 25–40%. Several factors have
been investigated to look for prognostic factors stratiﬁcations such as resection margins, node involvement in the primary disease,
and interval between the primary disease and liver metastases. Methods. We searched MEDLINE and EMBASE for studies that
reported ten-year survival. Metaanalysis was performed to analyse the eﬀect of recognised prognostic factors on cure rate for
colorectal metastases. The meta-analysis was performed according to Ottawa-Newcastle method of analysis for nonrandomised
trials and according to the guidelines of the PRISMA. Results. Eleven studies were included in the analysis, which showed a ten-
year survival rate of 12–36%. Factors that have favourable impact are clear resection margin, low level of CEA, single metastatic
deposit, and node negative disease. The only factor that excluded patients from cure is the positive status of the resection margin.
Conclusion. Predicted ten-year survival after liver resection for colorectal metastases varies from 12 to 36%. Only positive resection
margins resulted in no 10-year survivors. No patient can be excluded from consideration for liver resection so long the result is
negative margins.
1.Introduction
It is known that 60–70% of recurrent colorectal cancer in-
volves the liver and that the liver is the only involved organ in
35% of cases. Colorectal liver metastases used to be thought
of as systemic disease that involves many organs and systems
until recently when local liver therapy in the form of liver
resection has been reported to results in 5-year survival of
27–39% and even longer survival and cure [1, 2]. Patients
with liver metastases that are resectable but left untreated
have average survival of 6–12 months and rarely longer than
2y e a r s[ 3].
Over the last 20 years liver resection for colorectal me-
tastases has seen many reﬁnements; the improvement in an-
aesthesia and postoperative care have reduced the morbidity
and mortality with subsequent more aggressive surgical
approach. Strategies that have widened the indications for
liver resection includes portal vein embolisation, staged liver
resection, neoadjuvant chemotherapy, ablative procedures,
and locoregional chemotherapy [4–7].
Many studies have developed and validated scoring
systems to predict prognosis and recurrence of colorectal
metastases based on clinical and pathological data of large
numberofhepaticresectionsforcolorectalmetastases.These
scores are based on variety of factors that include stage of
the primary disease, time interval between diagnosis of the
primary lesion and occurrence of liver metastases, level of
CEA immediately prior to liver resection, size and number
of resected liver lesions, surgical resection margin, blood
transfusion, and bilateral distribution of liver disease [1, 8–
10].
Various factors were found to have inﬂuence on disease
recurrenceandoverallsurvival;resectionmarginsandlymph
nodes involvement are common predictors of recurrence.
Other controversial factors are number and size of lesions,
bloodtransfusion,anddisease-freeinterval.Otherfactorsare
extrahepatic disease and portal nodes metastases [11–14].
This systematic review is conducted to evaluate the risk
factors inﬂuence of overall long-term survival following
hepatic resection for colorectal metastases.2 ISRN Oncology
2. Methods
2.1. Search and Study Identiﬁcation. Electronic search was
performed and relevant reports were identiﬁed using elec-
tronic databases (MEDLINE 1950–2010 and EMBASE 1980–
2010), the search was restricted to human adults and English
language literature. The search terms used were colorectal
neoplasm, overall survival, and disease-free survival. All the
references used in the published original and review studies
were searched to identify more studies.
2.2. Criteria for Study Selection. To be included, studies had
to meet the following criteria.
(1) Design: prospective or retrospective cohort studies.
(2) Population: patients with liver metastases from col-
orectal cancer who had liver resection as a curative
treatment.
(3) Exposure: surgical liver resection for metastases
whether anatomic resection or segmental nonana-
tomic resection regardless of whether they had or
did not have adjuvant chemotherapy. That included
studies that evaluated patients’ survival following re-
resection following primary liver resection.
(4) Outcome: overall ten-year survival following liver re-
section for colorectal liver metastases.
Duplicate publications were excluded and wherever pub-
lications that evaluated the same population group were en-
countered, the report with the most relevant and compre-
hensive data was selected.
2.3. Data Extraction. Articles that met all the inclusion crite-
ria were retrieved as full text articles. Two independent re-
viewers using standard data collection form extracted all
relevant data from the full text articles. Inconsistencies were
resolved by discussion to reach a reasonable consensus.
Whenever missing data were encountered, the authors were
contacted to request the data required to be included in
the meta-analysis. One study in non-English language was
encountered and was excluded.
2.4. Quality Assessment. Methodological quality of the stud-
ies was evaluated independently by two reviewers using the
Newcastle-Ottawa Scale [15]. A quality score was calculated
on the basis of the following components: selection of the
study groups (0–4 points), quality of the adjustment for
confounding variables (0–2), and outcome of interest in the
study population (0–3 points). A higher score represents
better methodological quality.
2.5. Statistical Analysis. Odds ratio (OR) of overall survival
was used as the primary eﬀect estimate in this meta-analysis.
From the eligible studies that met the inclusion criteria,
estimates of the OR and its associated 95% conﬁdence
interval (CI) were calculated using the Review Manager
software (Version 5 for Windows, Copenhagen, Denmark;
The Nordic Cochrane Centre, The Cochrane Collaboration,
2008). Data that could not be extracted directly were
reconstructed indirectly by two reviewers when required.
Prespeciﬁed factors that was thought to aﬀect the overall
survival after liver resection for colorectal metastases were
analysed. Those included resection margin, tumour size,
number of metastases, bilateral versus unilateral disease, T
stage of the primary, lymph nodes positive primary versus
lymph nodes negative, disease-free interval, CEA level, and
blood transfusion. Sensitivity analysis on the included stud-
ies was conducted on the Review Manager.
Heterogeneity between the included studies was ap-
praised using the Q measure for statistical signiﬁcance and
the I2 measure for the amount of heterogeneity, with P<. 1
being statistically signiﬁcant and I2 > 25% showing impor-
tant heterogeneity. A random eﬀect model based on Der-
Simonian-Laird estimator was used wherever there was
signiﬁcant heterogeneity, and ﬁxed eﬀect model based on
Mantel-Haenszel estimator was used when there was no
signiﬁcant heterogeneity [16]. We conducted Begg’s test and
the Harbord modiﬁed test to identify publication bias for
small study eﬀect, with P>. 5 being statistically signiﬁcant
[17]. The results of this systematic review were reported
using the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [18].
3. Results
3.1. Study Characteristics and Methodological Quality. The
initial search revealed 164 titles, abstracts for those articles
(Figure 1) were reviewed, 28 articles were considered to
be potentially useful for inclusion, and their full text was
retrieved and reviewed. Seventeen of these 28 articles were
subsequentlyexcludedfromthemeta-analysisastheydidnot
meet the inclusion criteria. Eleven original reports (all ret-
rospective cohort studies) had enough data to investigate
the role of diﬀerent variables on overall long-term survival
after liver resection for colorectal metastases. Two studies
were excluded due to the fact that they were a duplication
of the same study population [19, 20]. One further study was
excluded because it had no data that can be used in the meta-
analysis [21]. The included studies were published between
1995 and 2009 (Table 1). The methodological quality of
the included studies is shown in (Table 2). There was no
statistical evidence of publication bias between the included
studies.
There was no statistical evidence of publication bias
among the included studies based on the funnel plot used
in Review Manager.
3.2. Patients Characteristics. The eleven studies reviewed
3442 patients who had liver resection for colorectal metas-
tases, the eight included studies had a total number of 2387
patients, all studies reported ﬁve- and ten-year survival [22–
29]. Overall 5-year survival was 21–51% and overall ten-year
survivalwas12–36%.Thesestudieshadvariablyreportedthe
impact of diﬀerent factors on overall survival; these factors
included resection margins, size of the largest liver lesion,
number of liver lesions, distribution of lesions, CEA levelsISRN Oncology 3
Table 1: Characteristics of the included studies.
Study Study design Total number of patients 5-year survival 10-year survival
Giuliante et al. 2009 [22] Retrospective 251 38.9% 24.2%
Hamady et al. 2006 [23] Retrospective 293 44% 36%
Jamison et al. 1997 [24] Retrospective 280 27% 20%
Minagawa et al. 2000 [25] Retrospective 235 38% 26%
Scheele et al. 1995 [26] Retrospective 469 39.3% 23.6%
Shimizu et al. 2007 [27] Retrospective 164 51.8% 36.6%
Tomlinson et al. 2007 [28] Retrospective 612 21% 17%
Wanebo et al. 1996 [29] Retrospective 74 24% 12%
Potentially relevant
studies (164)
Studies
excluded on
abstract (153)
Potentially suitable
studies
(11)
Studies
excluded
(3)
Studies included in
systematic review
(8)
Figure 1: Flow diagram of study selection process.
Table 2: Quality assessment of included studies (Newcastle-Ottawa
Scale).
Study Selection Comparability Outcome
Giuliante et al. 2009 [22]4 1 3
Hamady et al. 2006 [23]4 2 3
Jamison et al. 1997 [24]4 2 3
Minagawa et al. 2000 [25]4 1 3
Scheele et al. 1995 [26]4 2 3
Shimizu et al. 2007 [27]4 1 3
Tomlinson et al. 2007 [28]4 2 3
Wanebo et al. 1996 [29]4 2 3
prior to liver resection, lymph node status of the primary,
satellite conﬁguration of liver metastases, type of resection,
extrahepatic disease, and whether the liver metastases were
presentedinasynchronousormetachronoustothediagnosis
of the primary colorectal cancer.
3.3. Disease-Free Survival. In the study of Tomlinson et al.
[28] they reported that 34% of patients who are disease-free
at 5 years after hepatic resection did experience recurrence.
ThisﬁgureishighcomparedwithotherreportsbyMinagawa
et al., Giuliante et al., and Scheele et al. who reported 50-
and 10-year disease-free survival of 26 and 23%, 28.2 and
25.4%, and 33.6 and 25.4%, respectively [22, 25, 26]. From
these data we conclude that 5-year survival does not equate
cure. Since recurrence after 10-year of disease-free survival is
rare; ten-year survival could be considered as deﬁnitive cure.
Factors that inﬂuence disease-free survival and may
predictthathasbeenreportedonlyinthestudybyMinagawa
et al. [25], hence it was not suitable to conduct meta-analysis
on this category of outcome.
3.4.InﬂuenceofResectionMargins. Fourstudiesreportedad-
equate data to determine the relationship between positive
and negative resection margin and long-term survival. The
average overall survival for positive margin was 29%, which
is signiﬁcantly better compared with 20% of negative resec-
tion margin (P = .03) with odds ratio of 0.41 (95% CI
0.18–0.9). There was moderate degree of heterogeneity I2
52%; however, this heterogeneity was eliminated when pre-
speciﬁed sensitivity analysis was performed by elimination
of the study by Tomlinson et al. [28] that had a wide 95%
CI and that has little overlap with other studies. The result of
the meta-analysis after this elimination showed OR of 0.55
(0.95% CI 0.36–0.84) with P = .005, which ensures that the
results of the meta-analysis are robust (Figure 2).
Four studies reported the inﬂuence of wider negative
margin of more than 1cm compared with negative margin of
0–10mm [23–26] .W i d e rr e s e c t i o nm a r g i nh a dn ob e n e ﬁ c i a l
eﬀect on overall survival. Pooled analysis for the likelihood
of survival is shown in Figure 3 (OR = 1.11; 95% CI: 0.59–
2.08; P = .75). Moderate heterogeneity was seen. The pooled
estimate was robust: omission of individual study at a time
did not change the statistical results (data not shown).
Six studies reported the eﬀect of tumour size on overall
survival [22–26, 28]; meta-analysis of the studies that
reported analysis data on patients liver metastases more than
5cm compared with patients who had liver lesions of 5cm
or less, showed no prognostic relationship between size of
the resected tumour and overall patients’ survival. Figure 4
showstheresultsofpooledestimateforsurvivalinrelationto
tumour size (OR = 0.73, 95% CI: 0.46–1.16; P = .18). There
was moderate heterogeneity among the included studies
I2 = 75%, the results were robust, omission of the study by4 ISRN Oncology
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Figure 2: Positive and negative margins.
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Figure 3: Resection margin less than 1cm or more than 1cm.
Giuliante et al. [22] resulted in very close odds ratio and
removed the heterogeneity.
Four studies reported data on the eﬀect of time interval
between the diagnoses of the primary colorectal cancer and
the occurrence of liver metastases on the overall patients’
survival. Pooled estimate of the survival time after liver re-
section for colorectal metastases showed no signiﬁcant
prognostic relationship (OR = 1.22; 95% CI: 0.75–1.99; P =
.42) Figure 5. There was moderate degree of heterogeneity
(I2 = 68%). The analysis results were robust, exclusion of the
study by Scheele et al. [26] removed the heterogeneity and
theresultsandresultedinOR =1.03;95%CI:0.64–1.65,data
not shown.
Six studies reported data to determine the relationship
between lymph nodes metastasis status of the primary col-
orectal cancer and survival after liver resection for colorectal
metastases [22, 23, 25, 26, 28, 29]. Figure 6 shows the forest
plot with pooled estimates of the odds ratio of survival in
patients who had node positive primary disease compared
with those who had node negative disease. The overall ten-
year survival for node negative disease was 32% compared
with 22% for nodes positive primary disease (OR = 0.46;
95% CI: 0.26–0.79; P = .006), the pooled analysis showed
signiﬁcant heterogeneity I2 = 81%; omission of the study
by Tomlinson et al. [28] reduced the heterogeneity to
insigniﬁcant level with results of odds ratio of 0.38; 95%
CI: 0.23–6; P<. 0001, which ensures the robustness of the
pooled estimates of the eﬀect.
Three studies reported data for determination of the re-
lationship between types of liver resection (segmental or an-
atomic) [22, 25, 29]. Figure 7 shows the Forest plot of the
pooled estimates of long-term survival for patients who had
segmental resection compared with patients who had an-
atomic resection (right hepatectomy, left hepatectomy, or
trisectionectomy). The type of resection did not have any
signiﬁcant impact on overall survival (OR = 2.60; 95% CI:
0.88–7.63; P = .08), there was signiﬁcant heterogeneity
among the included studies. Omission of individual studies
did not change the results of the analysis.
3.5. CEA Levels. Four studies provided data for determining
the relationship of CEA levels, prior to resection of colorectal
liver metastases, and the overall patients’ survival [22, 23, 25,
26]. Figure 8 shows the Forest plot with the pooled estimate
for likelihood of ten-year survival for patients with CEA
levels more than 50ng/mL and those with CEA levels less
than 50ng/mL. Overall pooled survival for those with CEA
level less than 50ng/mL is 37% compared with 19% for
those with CEA greater than 50ng/mL. The results show
statistically signiﬁcant better survival in those with low CEA
levels (OR = 2.27; 95% CI: 1.03–5.02; P = .04). There isISRN Oncology 5
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Figure 4: Tumour size.
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Figure 5: Disease-free interval.
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Figure 6: Nodal disease of the primary cancer.6 ISRN Oncology
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Figure 7: Type of resection.
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Figure 8: CEA level.
signiﬁcant heterogeneity (I2 = 72%); omission of the study
byScheeleetal.[26],whichlookslike anoutlierhasremoved
the heterogeneity, and still the results were signiﬁcant (OR =
1.71; 95% CI: 1.15–2.55; P = .009; data not shown), which
conﬁrms the robust results of the analysis.
3.6. Distribution of Liver Lesions. Five studies provided data
to determine the eﬀect of bilateral distribution of resected
colorectal metastases on the ten-year survival [22, 25, 26,
28, 29]. Ten-year survival was 36% compared with 18% in
patients who had bilateral disease resected. Figure 9 shows
the Forest plot of the pooled estimate for ten-year sur-
vival, the presence of bilateral disease in the liver leads to
signiﬁcantlyreducedlong-term survival(OR =1.64; 95%CI:
1.19–2.27; P = .003. There was no signiﬁcant heterogeneity
among the included studies I2 = 0%.
3.7. Number of Liver Lesions. Seven studies reported data
to determine the eﬀect of the number of the resected liver
lesions on long-term survival [22–26, 28, 29]; these studies
compared survival in patients with four or less lesions versus
patients who had more than four lesions and found that
ten-year survival for patients with four or less lesion was
38% compared with 20% of those who had more than four
lesions (OR = 1.75; 95% CI: 0.87–3.51; P = .11); there was
a signiﬁcant heterogeneity I2 = 73%; omission of individual
studies made no statistical diﬀerence; however, omission of
three studies, Scheele et al., Minagawa et al., and Tomlinson
et al. [25, 26, 28] removes the heterogeneity and results in
signiﬁcantly better survival in patients who had four or less
lesions (OR = 2.26; 95% CI: 1.36–3.75; P = .002), data not
shown. This made it not possible to make any valid conclu-
sion about the eﬀect of lesion’s number on overall survival
(Figure 10).
3.8. Synchronous versus Metachronous Metastases. Six studies
provided data to determine the relationship of timing of liver
metastases; whether it was found at the time of diagnosis
of the primary colorectal cancer or afterward [22, 23, 25–
28]. Figure 11 shows the Forest plot with pooled estimate of
likelihood of survival for patients who had liver metastases
diagnosed synchronous with the primary colorectal cancer
compared with those who developed liver metastases after-
ward (metachronous; OR = 0.77; 95% CI: 0.59–1.01; P =
.06). The timing of liver metastases has no signiﬁcant eﬀect
on long-term survival.
3.9. Eﬀect of Blood Transfusion. Four studies provided data
for determining the relationship of blood transfusion, after
liver resection, and long-term survival [22–24, 29]. Figure 12
shows the Forest plot with the pooled estimate for long-
term survival. Patients who received two or less units hadISRN Oncology 7
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Figure 9: Distribution of liver lesions.
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Figure 10: Number of liver lesions.
signiﬁcantly better survival than patients who had more than
two units (OR = 3.69; CI: 1.79–7.60; P = .0004). There was
signiﬁcant heterogeneity among the included studies I2 =
63%. Omission of the study of Giuliante et al. [22]r e m o v e d
the heterogeneity, and the pooled estimate remained valid
(OR = 2.51; CI: 1.63–3.85; P<. 0001), data not shown.
Three studies provided data that compared the diﬀerence
in survival between patients who had a single lesion resected
and those who had more than a single lesion [22, 25, 29].
Figure 13 shows the Forest plot of the pooled estimates of
survival for patients with single lesion compared to patients
who had multiple lesions. Patients with a single lesions
had signiﬁcantly better prognosis than those with multiple
lesions (OR = 1.56; 95% CI: 1.08–2.25; P = .02).
T h r e es t u d i e sp r o v i d e dd a t at h a tc o m p a r e ds u r v i v a lo f
patients who had satellite lesions along with larger lesion
or lesions compared with those who had no satellite lesions
[23, 24, 26]. Figure 14 shows the Forest plot of the pooled
estimate of survival, the estimate shows signiﬁcantly better
survival for patients who had no satellite lesions compared
with those who had satellite lesions (OR = 0.37; CI: 0.18–
0.77; P = .008), there was signiﬁcant heterogeneity among
the included studies.
4. Discussion
Thissystematicreviewandmeta-analysisshowedthatfactors
that aﬀect long-term survival following hepatic resection, for
colorectal cancer metastases, include clear resection margins,
advanced primary colorectal cancer with nodal metastases,
CEA levels, distribution of liver lesions, timing of diagnosis
of liver metastases (synchronous or metachronous), quantity
of blood transfusion, single lesion compared with multiple
lesions, and presence or absence of satellite nodules close to
the main lesion. Patients who had clear resection margins
had signiﬁcantly better long-term survival than those with
positive resection margins. Patients who had early stage
colorectal cancer with no lymph nodes metastases had better
survival than those with lymph nodes metastases. It also
showed that metachronous presentation of liver metastases
is a good prognostic factor compared with synchronous
presentation. A single liver lesion particularly in the absence
of satellite nodules has better outcome than multiple lesions
withorwithoutsatellitenodules;however,whencomparison
was made between patients with more than four nodules and
those with four or less lesions, there was no diﬀerence in
overall long-term survival. CEA levels less than 50ng/mL,8 ISRN Oncology
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Figure 11: Synchronous versus metachronous metastases.
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Figure 12: Blood transfusion.
unilateral liver disease, and two units or less of perioperative
blood transfusion were found to be favourable prognostic
factors. There was no single prognostic factor of suﬃcient
p o w e rt op r e d i c tl o n g - t e r ms u r v i v a la n dc u r e .
Otherfactorsthatwereanalysedinthismeta-analysisand
foundnottohavesigniﬁcantinﬂuenceonlong-termsurvival
included a the width of resection margin, it was found that
if the resection margin is clear there is no survival beneﬁt
from a wider resection margin more than 1cm. Whether the
resected largest lesion was more or less than 5cm did not
have eﬀect on survival. The interval between the diagnosis of
theprimaryandliverrecurrencelessormorethan12months
did not seem to aﬀect long term survival. Whether the
lesionremovedinanatomicresectiontechniqueorsegmental
resection, number of resected lesions, and synchronous
versus metachronous metastases, all had no eﬀect on long-
term survival.
Duringthepasttwodecades,liverresectionforcolorectal
liver metastases has been increasing the standard of care
whenever the disease is limited to the liver and is techni-
cally possible by leaving adequate liver remnants. There is
overwhelming evidence to support the survival beneﬁt with
reportsofactuarial5-yearsurvivalof25–40%comparedwith
patients who are treated only with chemotherapy who rarely
survive up to ﬁve years [30, 31]. With technical advances and
improved perioperative the mortality of liver resection is less
than 5%, Wei et al. reported 1.7% mortality in a large series
with morbidity of 19% [21]. This improvement makes liver
resection a standard treatment for colorectal metastases [12,
20, 26, 28].
Tomlinson et al. had investigated risk factors for 10-year
survival and redesigned the original score devised by the
same investigators. The original score had ﬁve components
with one point for each component that includes tumour
number more than four, size more than 5cm, CEA level
more than 200ng/mL, and disease-free interval less than 12
months and positive resection margin with one point for
each. After analysing 10-year survival, patients fell in two
groups; the low risk group (0–2 points) who had 10-year
survival of 21% and high-risk group (3–5 points) with 10-
year survival of 10% (P<. 0001) [1, 28]. No patients with
positive resection margin had survived for 10 years, which
seems to be the only factor that ruled out any possibility of
cure [28]. This raises the question of the beneﬁt of neoadju-
vant chemotherapy particularly now there are more eﬀective
agents that may increase the rate of complete resection, the
eﬀect of that approach on survival is not known.ISRN Oncology 9
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Figure 13: Single versus multiple lesions.
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Figure 14: Satellite lesions.
It was not possible in this review to analyse the eﬀect of
adjuvant chemotherapy on survival after hepatic resection
forcolorectalmetastases.However,mostofthestudypatients
had been treated in the era when the standard chemotherapy
was 5-ﬂourouracil, which has limited eﬀect, compared with
the modern chemotherapeutic agents like irinotecan, oxali-
platin, and bevacizumab [28]. This makes the evaluation of
the pure curative beneﬁt from surgical resection relatively
diﬃcult to assess.
The improvement of outcome in liver resection has been
attributed to a combination of factors such as aggressive sur-
gical treatment, improved chemotherapy, and improvement
of preoperative imaging and patient selection [32–34].
Repeat hepatectomy for recurrent hepatic disease fol-
lowing initial liver resection is being increasingly used, also
staged liver resection and resection of isolated extrahepatic
disease is being more and more utilised with encouraging
results that lead to improvement in survival [4, 34–37].
Despite all the advances and improvements, it remains not
possible to discriminate with reasonable certainty which
subset of patients is likely to be cured or live more than 5
years. Repeat liver resection gives overall survival results of
up to 52% in one series and is comparable to the results of
initial liver resection [37].
Improvement of preoperative staging by liberal use of
helical CT scans and MRI and the introduction of PET scan
and PET CT have allowed for better patients selection by
early detection of extrahepatic and bilobar disease [33, 38–
40].
Many authors have reported using radiofrequency abla-
tion in conjunction with surgery for nonresectable liver me-
tastases either intraoperative or postoperative with variable
results [21, 32], the impact of this technique on overall long-
term survival remains questionable.
The emergence of new chemotherapeutic agents such as
oxaliplatin, irinotecan, and bevacizumab has increased the
treatment option available for clinicians to deal with meta-
static colorectal disease. These new agents have been used in
conjunction with liver resection either as neoadjuvant or
adjuvant manner in many studies but the eﬀect of this ap-
proach on survival has not been test in a randomised con-
trolled trial [5, 41, 42]. Chemotherapy is being commonly
used as an adjuvant agents following liver resection partic-
ularly in patients who had no previous chemotherapy, the
survival beneﬁt of this approach remains to be proved [21].
Another potential use is to downstage potentially resectable
liver metastases, in this situation patients with advanced dis-
ease are oﬀered resection if they show good response to
chemotherapy, this strategy has been used with limited suc-
cess [5, 34].
In conclusion this review deﬁnes 10-year survival and
cure to be between 12% and 28%; we described the factors
that aﬀect survival in this meta-analysis. There is no single
factor that was of suﬃcient power to rule out cure with10 ISRN Oncology
the possible exception of positive resection margin. This
leads to the fact that patients’ selection for resection with
disease limited to the liver or liver disease with resectable
extrahepatic metastases remains a matter of trial and error
particularly for patients who have marginal suitability for
resection. This review also indicates that we need newer
prognostic factors perhaps based on tumour biology that
may discriminate between curable and noncurable metastat-
ic colorectal cancer. An important limitation of this study
that reﬂects the quality of the available data is the fact that
raw data was not available to all the studies’ patients and the
presence of heterogeneity among the included studies and
the fact that those studies are generally retrospective reviews.
Alsopatientswhohad10-yearsurvivalarelikelytohavebeen
treated prior to the era of PET scan routine use and likely
have been treated with old and less eﬀective chemotherapeu-
tic agents.
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